Cargando…
Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine‐based high‐dose chemotherapy regimen
High‐dose chemotherapy (HDT) with autologous stem cell transplantation is the standard of care for relapsed/refractory (RR) Hodgkin lymphoma (HL). Given that HDT may cure a sizeable proportion of patients refractory to first salvage, development of newer conditioning regimens remains a priority. We...
Autores principales: | Musso, Maurizio, Messina, Giuseppe, Di Renzo, Nicola, Di Carlo, Paolo, Vitolo, Umberto, Scalone, Renato, Marcacci, Gianpaolo, Scalzulli, Potito R., Moscato, Tiziana, Matera, Rossella, Crescimanno, Alessandra, Santarone, Stella, Orciuolo, Enrico, Merenda, Anxur, Pavone, Vincenzo, Pastore, Domenico, Donnarumma, Daniela, Carella, Angelo M., Ciochetto, Chiara, Cascavilla, Nicola, Mele, Anna, Lanza, Francesco, Di Nicola, Massimo, Bonizzoni, Erminio, Pinto, Antonello |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053328/ https://www.ncbi.nlm.nih.gov/pubmed/26458240 http://dx.doi.org/10.1111/bjh.13803 |
Ejemplares similares
-
Every‐other‐day palonosetron plus aprepitant for prevention of emesis following induction chemotherapy for acute myeloid leukemia: A randomized, controlled study from the “Rete Ematologica Pugliese”
por: Di Renzo, Nicola, et al.
Publicado: (2019) -
Complete response induced by fotemustine given as single agent in a patient with primary central nervous system non-Hodgkin aggressive lymphoma relapsed after high-dose chemotherapy and autologous stem cell support
por: Pennese, Elsa, et al.
Publicado: (2011) -
Regulation of Inflammatory and Proliferative Pathways by Fotemustine and Dexamethasone in Endometriosis
por: Genovese, Tiziana, et al.
Publicado: (2021) -
Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas
por: Corazzelli, Gaetano, et al.
Publicado: (2011) -
Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high ‘life threat’ impact cardiopathy
por: Corazzelli, Gaetano, et al.
Publicado: (2011)